title: Nifuratel-containing initial anti-Helicobacter pylori triple therapy in children.
abstract: BACKGROUND
  Proton pump inhibitor-containing triple therapy with amoxicillin and metronidazole is recommended as initial treatment of Helicobacter pylori in childhood. However, eradication rate with this "classic" regimen is relatively low in Russia.
  
  
  OBJECTIVE
  To evaluate empiric nifuratel, amoxicillin, and bismuth triple therapy for H. pylori gastritis in childhood.
  
  
  METHODS
  Pediatric outpatients with H. pylori-associated chronic gastritis who underwent endoscopy for dyspeptic symptoms received the combination of bismuth subcitrate (8 mg/kg/day, q.d.s.), nifuratel (30 mg/kg/day, q.d.s.), and amoxicillin (50 mg/kg/day, q.d.s.) for 10 days. H. pylori status was determined before and after the treatment (in 4-6 weeks) by modified Giemsa staining.
  
  
  RESULTS
  Seventy-three children (48 boys, 25 girls, age range 9-14) were entered. H. pylori was eradicated in 63 patients (86%; 95% confidence interval: 76.6-93.2; intention-to-treat and per protocol). There were no serious adverse reactions and were no withdrawals due to any side-effects. All of side-effects were self-limiting (dark stools, urine discoloration, blackening of the tongue, and others).
  
  
  CONCLUSIONS
  The combination of nifuratel, bismuth subcitrate, and amoxicillin was an effective and tolerable regimen for H. pylori eradication.
authors.affiliation: Children's Republican Hospital, Ufa, Russia. aanj@rambler.ru
authors.forename: Alexander A
authors.initials: AA
authors.lastname: Nijevitch
authors.forename: Valery U
authors.initials: VU
authors.lastname: Sataev
authors.forename: Elsa N
authors.initials: EN
authors.lastname: Akhmadeyeva
authors.forename: Alexander G
authors.initials: AG
authors.lastname: Arsamastsev
mesh_terms: D000293:Adolescent; D000658:Amoxicillin / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D005756:Gastritis / Q000188:drug therapy / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000472:pathogenicity; D006801:Humans; D008297:Male; D009545:Nifuratel / Q000009:adverse effects / Q000627:therapeutic use*; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000188:drug therapy / Q000382:microbiology; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D009942:Organometallic Compounds; D000658:Amoxicillin; C002791:bismuth tripotassium dicitrate; D009545:Nifuratel